Heart failure & cardiomyopathies
Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP
Authors' conclusion
SVEP1 improved the predictive performance of conventional models, including known clinical parameters with or without NT-proBNP, to predict future MACE in patients with hypertrophic cardiomyopathy.
Study context
- Population
- Patients with hypertrophic cardiomyopathypatients with hypertrophic cardiomyopathy
- Participants
- 610 patients
- Predictors
- SVEP1 added to the 15 clinical predictors with or without NT-proBNP
- Predicted outcome
- MACE defined as heart failure hospitalization or cardiac death (time to first MACE)
Methodological detailsLasso-regularized Cox proportional hazards model, 10-fold cross-validation
- Lasso-regularized Cox proportional hazards model
- 10-fold cross-validation
Model performance
As reported in the abstract
C statistic
Clinical plus NT-proBNP model with SVEP1 added
0.87(0.83-0.91)
Clinical plus NT-proBNP model
0.82(0.78-0.86)
Clinical plus SVEP1 model
0.86(0.82-0.91)
- Clinical plus NT-proBNP model with SVEP1 added vs clinical plus NT-proBNP model: P = 0.01
- Clinical plus SVEP1 model vs clinical plus NT-proBNP model: P = 0.04
- C statistics using 10-fold cross-validation
Further findings
| Outcome | Adjusted hazard ratio (95% CI) | P value | |
|---|---|---|---|
| MACE in the low NT-proBNP groupsHigh SVEP1 groupvs low SVEP1 groupAdjusted for 15 clinical predictors | 4.52 (1.05–19.4) | P = 0.042 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
- Major adverse cardiovascular events (MACE) in the low NT-proBNP groups: 4 groups stratified by the median levels of SVEP1 and NT-proBNP
Original publication
Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP. Circ Heart Fail. Published 20 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →